Pfizer withdrew Oxbryta (voxelotor), a conditionally approved oral therapy for SCD, saying its benefits don't outweigh risks.

Pfizer anticipates revenue growth, driven by oncology investments, M&A activities, and manufacturing optimization. See why ...

Healthcare professionals have been urged to stop supplying Oxbryta “immediately” after new data revealed “an unfavourable imbalance” of “fatal events” and “acute painful crises” in patients on the ...

The sickle cell treatment voxelotor (Oxbryta) has been withdrawn from all markets by the manufacturer Pfizer after a “higher than anticipated” number of deaths were reported and clinical evidence ...

Pfizer has divested a $3.3 billion stake in Haleon, reducing its holding in the British consumer healthcare company.

Good morning! What would you buy if you earned $305 million in one year? Maybe I'd have a different color KitchenAid mixer for every season. Bird flu: ...

Pfizer recalled Oxbryta and ended clinical trials over safety concerns, but sickle cell advocates are warning that stopping the drug abruptly could be dangerous.

The questions of drugs, real and spurious, has come up in the healthcare sector this week, with reports of drugs not meeting ...

Companies in the Consumer Goods sector have received a lot of coverage today as analysts weigh in on The Hershey Company (HSY – Research ...

In a report released today, Liisa Bayko from Evercore ISI maintained a Buy rating on Vertex Pharmaceuticals (VRTX – Research Report), ...

Pfizer (NYSE:PFE) has reduced its ownership in the British consumer healthcare giant Haleon (NYSE:HLN) to 15% from 22.6% by ...

Israeli troops crossed the border for the first time since 2006 in a ground operation targeting Hezbollah. The Israeli military called for evacuations in southern Lebanon. As a Crisis Builds ...